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InsOBJECTIVES The aim of this study was to assess the incidence and clinical impact of balloon post-dilation (BPD)
after transcatheter aortic valve replacement (TAVR) with the CoreValve prosthesis (Medtronic Inc., Minneapolis,
Minnesota).
BACKGROUND BPD is a widely adopted strategy to reduce the degree of paraprosthetic regurgitation in case
of transcatheter heart valve underexpansion. However, controversies still remain regarding its real effectiveness
and safety.
METHODS The ClinicalService (a nation-based data repository and medical care project) dataset was analyzed. All
patients were dichotomized according to the need for BPD during the index procedure.
RESULTS Among 1,376 patients, BPD of the transcatheter heart valve was performed in 272 (19.8%). In 37% of cases, it
was unsuccessful at reducing the paravalvular regurgitation to mild or less. No case of valve embolization, new
intravalvular regurgitation, coronary occlusion, and aortic root injury occurred during BPD. There were no statistically
signiﬁcant differences between the 2 groups in the incidence of in-hospital all-cause and cardiovascular mortality,
neurological events, myocardial infarction, bleeding, conversion to open-chest surgery, and the need for a permanent
pacemaker. The need for BPD did not emerge as an independent risk factor for all-cause (adjusted hazard ratio [HR]: 1.33,
95% conﬁdence interval [CI]: 0.81 to 2.19, p ¼ 0.264) and cardiovascular (adjusted HR: 1.48, 95% CI: 0.74 to 2.97,
p ¼ 0.265) mortality at 1 year after the procedure. In addition, BPD did not predispose to higher odds of neurological
events during 12 months after TAVR (HR: 0.92, 95% CI: 0.45 to 1.88, p ¼ 0.815).
CONCLUSIONS This large study showed that BPD after TAVR was safe and not associated with increased rates of
cerebrovascular events, mortality, myocardial infarction, and aortic root injury. (J Am Coll Cardiol Intv 2014;7:1014–21)
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BPD = balloon post-dilation
CI = conﬁdence interval
HR = hazard ratio




TAVR = transcatheter aortic
valve replacement
THV = transcatheter heart
valve
VASC = Valve Academic
Research Consortium
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1015T ranscatheter aortic valve replacement (TAVR)has matured into a viable treatment alterna-tive for patients with severe aortic stenosis
at high-risk of conventional surgical aortic valve
replacement (1,2). Although associated with excellent
hemodynamic results, residual paravalvular regurgi-
tation (PVR) occurs frequently with this procedure,
having been reported in 80% to 96% of TAVR cases
(3). Moderate or severe PVR occurs in w10% to 15% of
procedures, and this was observed to produce signiﬁ-
cantly worse outcomes (2,3).
Balloon post-dilation (BPD) has been shown to be a
feasible and effective strategy to reduce signiﬁcant
PVR by enabling better expansion of the stent frame
containing the biological valve and thus improved
sealing (4). However, this technique is ineffective
when PVR is caused by a “too high” or “too low” im-
plantation, and some argue that post-dilation itself
may potentially increase the risk of iatrogenic cere-
brovascular events (5,6). However, these latter ob-
servations come from a few single-center studies with
relatively small populations. The aim of this large
multicenter analysis was to evaluate the prevalence of
BPD after TAVR with a self-expanding prosthesis and
its relative impact on clinical outcomes.
METHODS
PATIENT POPULATION. Starting in June 2007,
all consecutive patients with severe aortic stenosis
undergoing TAVRwith the third-generation 18-French
CoreValve device (Medtronic Inc., Minneapolis,
Minnesota) at 7 Italian centers were prospectively
included in the ClinicalService Project. This is a nation-
based clinical data repository and medical care project
aims to describe and improve the use of implantable
devices in clinical practice in Italy. The project was
approved by each site’s institutional review board or
medical director and conforms to the principles out-
lined in the Declaration of Helsinki. Each patient
signed an informed consent for data collection and
analysis. Clinical and echocardiographic follow-up
were performed according to each center’s clinical
practice. Eligibility for TAVR was established at each
center based on the consensus of a local multidisci-
plinary team, including clinical cardiologists, cardiac
surgeons, and cardiac anesthesiologists. Sizing of the
transcatheter heart valve (THV) was carried out byis on the Advisory Board of Medtronic and a consultant for Direct Flow M
are consultants for Medtronic. All other authors have reported that they ha
paper to disclose.
Manuscript received January 10, 2014; revised manuscript received March 1using multidetector computed tomography
and an integration of echocardiography
(transthoracic and/or transesophageal), angi-
ography and simultaneous aortography dur-
ing balloon valvuloplasty (7), according to
each center’s local practice. All the procedures
were approved for compassionate use in pa-
tients considered at high risk of surgery.
Clinical and echocardiographic follow-up
were performed at 30 days and 1 year by clin-
ical visits or telephone contacts. All events
were site reported. Patients were dichoto-
mized according to the need for BPD after
release of the CoreValve prosthesis at the in-
dex procedure.PROCEDURE. Design features of the CoreValve pros-
thesis and technical details of the procedure were
previously described (8–10). The CoreValve prosthesis,
available in the 26-mm and 29-mm sizes and, starting
September 2011 and August 2012, even in the 31-mm
and 23-mm sizes, was implanted using the trans-
femoral, subclavian, and transaortic approaches with
an 18-French delivery catheter, later improved by the
use of the AccuTrak Stability Layer (Medtronic Inc.).
All procedures were performed with patients under
local anesthesia or general anesthesia and endotra-
cheal intubation under ﬂuoroscopic guidance. After
prosthesis deployment, BPD was carried out under
rapid pacing to reduce signiﬁcant PVR or to optimize
the frame expansion. Indications and technique of
BPD were left to operators’ practice. Intraprocedural
quantiﬁcation of PVR severity was carried out by using
either echocardiography (Valve Academic Research
Consortium criteria) or hemodynamic parameters ac-
cording to the local institutional policies. The degree
of PVR was further assessed by a transthoracic echo-
cardiogram performed before discharge.
STATISTICAL ANALYSIS AND DEFINITIONS.
Descriptive statistics are reported as mean  SD for
normally distributed continuous variables or as
median and 25th to 75th percentile (interquartile
range) otherwise. Normality of distribution was
tested by means of the Kolmogorov-Smirnov test.
Absolute and relative frequencies are reported for
categorical variables. Continuous Gaussian variables
were compared by means of a Student t test for in-
dependent samples, whereas skewed distributionsedical. Drs. Bedogni, Ettori, Bruschi, and Petronio
ve no relationships relevant to the contents of this
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TABLE 1 Baseline Clinical and Echocardiographic Characteristics
Overall BPD Group No-BPD Group p Value
Clinical variables
Age, yrs 81.6  6.5 80.5  7.9 81.9  6.1 0.007
Female 52.5 (723/1,376) 38.2 (104/272) 56.1 (619/1,104) <0.001
Hypertension 81.3 (1,117/1374) 80.8 (219/271) 81.4 (898/1103) 0.820
Diabetes mellitus 29.1 (398/1,370) 26.8 (72/269) 29.6 (326/1,101) 0.357
Atrial ﬁbrillation 5.4 (74/1374) 5.9 (16/271) 5.3 (58/1103) 0.673
Previous myocardial
infarction
17.6 (241/1,370) 18.1 (49/270) 17.5 (192/1100) 0.789
Previous stroke/TIA 11.3 (155/1376) 14.3 (39/272) 10.5 (116/1,104) 0.073
Previous CABG 14.8 (203/1,374) 18.1 (49/271) 14.0 (154/1,103) 0.087
Previous PCI 30.1 (412/1,368) 26.6 (72/271) 31.0 (340/1,097) 0.007
PVD 29.3 (403/1,374) 33.2 (90/271) 28.4 (313/1,103) 0.117
COPD 23.7 (325/1,374) 24.7 (67/271) 23.4 (258/1,103) 0.644
CRF* 25.9 (308/1,191) 23.9 (58/243) 26.4 (250/948) 0.427
Previous PPM 13.1 (174/1,326) 14.0 (37/264) 12.9 (137/1,062) 0.631
NYHA functional
class III or IV
73.4 (1010/1,376) 80.9 (220/272) 71.6 (790/1,104) 0.002
Previous SAVR 2.4 (33/1,374) 4.1 (11/271) 2.0 (22/1,103) 0.047
STS score, % 7.1 (4–13) 7.5 (4–14) 6.9 (5–13) 0.711
Echocardiographic variables
LVEF, % 50.7  12.6 48.0  13.7 51.4  12.2 0.001
Mean aortic gradient,
mm Hg
51.7  15.5 51.8  15.7 51.7  15.4 0.430
AVA, cm2 0.4  0.2 0.4  0.2 0.4  0.2 0.610
Moderate or severe MR 44.9 (583/1,297) 53.8 (135/251) 42.8 (448/1,046) 0.002
Values are mean  SD or n/N (%). *Deﬁned as a glomerular ﬁltration rate <30 ml/min.
AVA ¼ aortic valve area; BPD ¼ balloon post-dilation; CABG ¼ coronary artery bypass graft; COPD ¼ chronic
obstructive pulmonary disease; CRF ¼ chronic renal failure; LVET ¼ left ventricular ejection fraction; MR ¼mitral
regurgitation; NYHA¼ New York Heart Association; PCI¼ percutaneous coronary intervention; PPM¼ permanent
pacemaker; PVD ¼ peripheral vascular disease; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of
Thoracic Surgery; TIA ¼ transient ischemic attack.
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1016were compared using the Mann-Whitney nonpara-
metric test. Differences in proportions were
compared by applying a chi-square analysis. Time to
long-term outcomes was described by means of the
Kaplan-Meier curve and compared between groups by
means of the log-rank test.Variables
Overall BPD Group No-BPD Group p Value
0.996
81.1 (1,116/1,376) 81.3 (221/272) 81.1 (895/1,104)
14.4 (198/1,376) 14.3 (39/272) 14.4 (159/1,104)
4.5 (62/1,376) 4.4 (12/272) 4.5 (50/1,104)
26.7 (368/1,376) 22.1 (60/272) 27.9 (308/1,104) 0.051
4.9 (68/1,374) 14.0 (38/271) 2.7 (30/1,103) <0.001
0.001
47.3 (650/1,374) 32.5 (88/271) 51.0 (562/1,103)
45.6 (627/1,374) 54.6 (148/271) 43.4 (479/1,103)
6.6 (90/1,374) 12.9 (35/271) 5.0 (55/1,103)
100.0 (65–127) 120.0 (140–240) 98.0 (60–127) <0.001
nge).
tion.After testing for proportional hazard assumptions,
Cox models were ﬁtted considering all variables from
Tables 1 and 2, and hazard ratios (HRs) with 95%
conﬁdence intervals (95% CIs) were computed. A Cox
multivariable analysis including all variables with
probability value <0.15 in each Cox univariate
analysis was used to determine independent pre-
dictors of the outcomes. All statistical analyses were
performed using SAS version 9.3 for Windows (SAS
Institute, Inc., Cary, North Carolina). All outcomes
were reported according to VARC criteria (11).
RESULTS
PATIENT POPULATION. Of 1,376 patients, BPD was
performed in 272 (19.8%). Clinical and echocardio-
graphic characteristics of the overall population, as
well as those of the BPD and no-BPD patients, are
summarized in Table 1. Compared with no BPD
patients, those in the BPD group were younger (80.5 
7.9 years vs. 81.9  6.1 years; p ¼ 0.007). Signiﬁcant
differences were also seen between the 2 groups in
terms of the prevalence of male sex, New York Heart
Association functional class III or IV, and degenerated
surgical aortic bioprosthesis, which were more
frequent in the BPD group (Table 1). Conversely, pre-
vious percutaneous coronary intervention was more
frequent among no-BPD patients. Additionally, BPD
patients had lower left ventricular ejection fraction
and more frequently reported baseline moderate/
severe mitral regurgitation and aortic regurgitation
(Table 1). There were no differences between these
2 groups in terms of other preoperative variables.
PROCEDURAL AND IN-HOSPITAL OUTCOMES.
Main procedural variables are presented in Table 2.
The transfemoral approach was the most frequently
used (81.1%), followed by the transsubclavian (14.4%)
and transaortic (4.5%) approaches, with no differ-
ences between the 2 groups (p ¼ 0.996). BPD was
more frequently performed when the 29-mm
(54.6% vs. 43.4%) and the 31-mm (12.9% vs. 5.0%)
prostheses were implanted (p < 0.001) and when a
second CoreValve was required as a bailout procedure
for acute implant failure (14.0% vs. 2.7%; p < 0.001).
The balloon sizes used for BPD for each THV size are
listed in the Table 3. Neither valve embolization nor
aortic root injury and coronary occlusion occurred
during BPD. There were no statistically signiﬁcant
differences between the 2 groups in the incidence of
in-hospital all-cause and cardiovascular mortality,
neurological events, myocardial infarction, bleeding,
and conversion to open-chest surgery. Of note, a
trend toward a higher rate of high-degree conduc-
tion disturbances requiring permanent pacemaker
TABLE 3 Balloon Sizes Used for BPD
CoreValve
26 mm 29 mm 31 mm
Balloons, mm
20 3.6 (3/83) 0.0 (0/144) 0.0 (0/31)
22 13.3 (11/83) 0.7 (1/144) 0.0 (0/31)
23 14.5 (12/83) 3.5 (5/144) 0.0 (0/31)
24 1.2 (1/83) 1.4 (2/144) 0.0 (0/31)
25 56.6 (47/83) 24.3 (35/144) 16.1 (5/31)
26 3.6 (3/83) 6.9 (10/144) 0.0 (0/31)
27 0.0 (0/83) 0.7 (1/144) 0.0 (0/31)
28 7.2 (6/83) 58.4 (84/144) 71.0 (22/31)
29 0.0 (0/83) 2.1 (3/144) 0.0 (0/31)
30 0.0 (0/83) 2.1 (3/144) 12.9 (4/31)
Values are % (n/N). In 14 patients, balloon size for BPD was not available.
No patients received 23-mm CoreValve (Medtronic, Minneapolis, Minnesota).
BPD ¼ balloon post-dilation.
TABLE 4 In-Hospital and 30-Day Outcomes
Overall BPD group No-BPD group p Value
In-hospital
All-cause mortality 4.1 (56/1,376) 4.4 (12/272) 4.0 (44/1,104) 0.750
Cardiovascular mortality 3.0 (41/1,376) 2.9 (8/272) 3.0 (33/1,104) 0.967
Stroke/TIA 2.2 (30/1,376) 2.2 (6/272) 2.2 (24/1,104) 0.974
Major stroke 1.3 (18/1,376) 2.2 (6/272) 1.1 (12/1,104) 0.146
Minor stroke 0.3 (4/1,376) 0.0 (0/272) 0.4 (4/1,104) 1.000
TIA 0.6 (8/1,376) 0.0 (0/272) 0.7 (8/1,104) 0.368
Life-threatening bleeding 4.7 (64/1,376) 3.7 (10/272) 4.9 (54/1,104) 0.394
Major bleeding 13.0 (179/1,376) 11.4 (31/272) 13.4 (148/1,104) 0.378
Myocardial infarction 1.2 (16/1,376) 1.5 (4/272) 1.1 (12/1,104) 0.597
Cardiac tamponade 2.0 (27/1,376) 2.6 (7/272) 1.8 (20/1,104) 0.417
New PPM 24.0 (330/1,376) 29.0 (79/272) 22.7 (251/1,104) 0.092
New LBBB 31.3 (431/1,376) 26.1 (71/272) 32.6 (360/1,104) 0.038
Conversion to surgery 0.4 (6/1,376) 0.4 (1/272) 0.5 (5/1,104) 0.848
Coronary occlusion 0.0 (0/1,376) 0.0 (0/272) 0.0 (0/1,104) —
AKI stage
1 15.6 (187/1,201) 16.5 (40/243) 15.3 (147/958)
2 2.6 (31/1,201) 2.1 (5/243) 2.7 (26/958) 0.902
3 1.8 (22/1,201) 2.1 (5/243) 1.8 (17/958)
PVR more than mild 20.0 (230/1,150) 37.9 (91/240) 17.1 (139/810) <0.001
30-day
All-cause mortality 5.9 (81/1,376) 6.6 (18/272) 5.7 (63/1,104) 0.567
Cardiovascular mortality 3.5 (48/1,376) 4.4 (12/272) 3.3 (36/1,104) 0.354
MI 1.3 (18/1,376) 1.5 (4/272) 1.3 (14/1,104) 0.792
Stroke/TIA 2.5 (35/1,376) 2.9 (8/272) 2.4 (27/1,104) 0.642
Major stroke 1.5 (21/1,376) 2.6 (7/272) 1.3 (14/1,104) 0.116
Minor stroke 0.5 (7/1,376) 0.0 (0/272) 0.6 (7/1,104) 0.188
TIA 0.7 (3/1,376) 0.4 (1/272) 0.7 (8/1,104) 0.513
Values are % (n/N).
AKI ¼ acute kidney injury; LBBB ¼ left bundle branch block; PVR ¼ paravalvular regurgitation; other
abbreviations as in Table 1.
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1017implantation was reported in the BPD group, whereas
a statistically signiﬁcant higher rate of left bundle
branch block was reported in the no-BPD group
(26.1% vs. 32.6%; p ¼ 0.038) (Table 4). Conversion to
surgery occurred in 6 patients: 3 had left ventricular
perforation caused by the stiff guidewire, 1 patient
had aortic dissection caused by delivery catheter
trauma, 1 early patient had THV embolization in the
ascending aorta and it was decided to convert the
procedure to conventional open-chest valve replace-
ment, and the last patient had annular rupture during
valvuloplasty before THV implantation.
On echocardiography, no differences in terms of
residual transprosthetic gradient were reported in the
2 groups, whereas residual PVR more than mild was
still more frequently observed in the BPD group
(37.9% vs. 17.1%; p < 0.001).
ONE-YEAR OUTCOMES. Kaplan-Meier curves depic-
ting all-cause mortality, cardiovascular mortality, and
neurological events for the BPD and no-BPD groups
are reported in Figures 1 to 3. The need for BPD was
associated with higher all-cause (hazard ratio [HR]:
1.43, 95% conﬁdence interval [CI]: 1.03 to 1.98, p ¼
0.036) and cardiovascular (HR: 1.59, 95% CI: 1.01 to
2.51, p ¼ 0.046) mortality, whereas this technique was
not associated with an increased hazard of neuro-
logical events >1 year after TAVR (HR: 0.92, 95% CI:
0.45 to 1.88, p ¼ 0.815). Other univariate predictors of
all-cause and cardiovascular mortality are shown in
Tables 5 and 6.
After adjustment for confounders by multivariable
analysis, moderate or greater residual PVR (adjusted
HR: 2.36, 95% CI: 1.56 to 3.56, p < 0.001), baseline
atrial ﬁbrillation (adjusted HR: 1.62, 95% CI: 1.04 to
2.52, p ¼ 0.034), and severe renal insufﬁciency
deﬁned as a glomerular ﬁltration rate <30 ml/min
(adjusted HR: 1.79, 95% CI: 1.17 to 2.73, p ¼ 0.004)
were found to be independently associated with
all-cause mortality. Independent predictors of car-
diovascular mortality were age (adjusted HR: 0.96,
95% CI: 0.92 to 0.99, p ¼ 0.014), and moderate or
greater residual PVR (adjusted HR: 2.60, 95% CI: 1.54
to 4.67, p ¼ 0.001). Of note, when forced into the
model, BPD did not emerge as being independently
associated with all-cause (adjusted HR: 1.33, 95% CI:
0.81 to 2.19, p ¼ 0.264) and cardiovascular (adjusted
HR: 1.48, 95% CI: 0.74 to 2.97, p ¼ 0.265) mortality. In
contrast, when moderate or greater residual PVR was
excluded as a possible predictor from the multivari-
able analysis, BPD emerged as an independent pre-
dictor of both all-cause (adjusted HR: 1.48, 95% CI:
1.00 to 2.18, p ¼ 0.048) and cardiovascular (adjusted
HR: 1.73, 95% CI: 1.02 to 2.95, p ¼ 0.043) mortality.
FIGURE 2 1-Year I
Kaplan-Meier surviva
transcatheter aortic
FIGURE 1 1-Year Incidence of All-Cause Mortality
Kaplan-Meier survival curves at 1-year follow-up depending on balloon post-dilation after
transcatheter aortic valve replacement. CI ¼ conﬁdence interval.
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Post-dilation of a THV is a widely adopted strategy to
reduce the degree of paraprosthetic regurgitation in
case of frame underexpansion or inadequate sealing
(12). The feasibility and indications of this tech-
nique have already been described (4,12). However,
controversies still remain regarding its real effec-
tiveness and safety. In particular, although BPD doesncidence of Cardiovascular Mortality
l curves at 1-year follow-up depending on balloon post-dilation after
valve replacement. CI ¼ conﬁdence interval.not seem to affect the valve performance, 2 single-
center studies (encompassing about one-fourth of
patients included in the present analysis) suggested
that this comes at the price of a higher risk of cerebral
embolization (5,6).
The present large multicenter analysis adds
meaningfully to the understanding of the impact
of BPD during TAVR with the self-expanding
CoreValve prosthesis with the following observa-
tions. First, balloon post-dilation was performed in
almost 20% of cases, and it was more frequently done
when the larger valves (29 and 31 mm) were implan-
ted and after a second prosthesis was required to treat
an acute implant failure. Second, in 37% of cases, BPD
was unsuccessful at reducing PVR to mild or less.
Third, BPD was not associated with higher rates of in-
hospital and 30-day mortality and neurological
events. Finally, after adjustment for confounders,
BPD was not found to be an independent predictor of
all-cause and cardiovascular mortality at 1 year.
The prevalence of post-dilation in this series was
w20%. In literature, the adoption rate of this bailout
strategy varies widely (from 9% to 29%), reﬂecting
different thresholds for BPD across TAVR centers (12).
Consistent with previous observations with the
balloon-expandable transcatheter prosthesis (5,6), we
reported a higher frequency of BPD in patients
receiving larger valve sizes, supporting the intuitive
idea that the larger the diameter of the prosthesis, the
lower the radial force expressed by the frame of the
THV to the landing zone of the aortic annulus, thus
requiring BPD to obtain greater expansion. Alterna-
tively, 31-mm valves may have been placed in very
large anatomy with suboptimal results, causing higher
BPD rates.
We reported a success rate of balloon post-dilation
of w63%. These data are in line with those reported
by previous studies with balloon-expandable valves
(5,6,13). The possible explanations for these fairly
disappointing results may be several. First, the cal-
cium burden located in the aortic valve is very high.
It has been reported that the degree of valve calciﬁ-
cation contributes to nonoptimal success of BPD,
precluding a complete sealing of the paravalvular
space or favoring recoil phenomena of the prosthesis
frame (5). Second, balloon post-dilation is performed
inappropriately or with an undersized balloon; as
matter of fact, when the cause of PVR is a “too low”
or “too high” implant, as well as the deployment of
an undersized THV, any attempt at further frame
dilation is generally futile (12). In these cases, the
best options to decrease the degree of PVR is to
implant a second prosthesis in a Valve-in-Valve
fashion (14) or, in the case of the CoreValve device,
FIGURE 3 1-Year Incidence of Stroke
Kaplan-Meier survival curves at 1-year follow-up depending on balloon post-dilation after
transcatheter aortic valve replacement. CI ¼ conﬁdence interval.
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1019to snare the ﬁrst valve out from its anatomic posi-
tion and deploy a second one (4). With these con-
siderations in mind, we can argue that more
aggressive pre-dilation and stricter indications for
BPD in very selected cases (only overt frame under-
expansion, avoiding it in the cases of evident low or
high deployment) might be successful in improving
the outcomes of this bailout technique.
In terms of clinical outcomes, the results of this
study tend to support the safety of BPD immediately
after valve implantation to reduce the incidence of
PVR after TAVR with self-expanding valves. No cases
of intraprosthetic regurgitation, coronary occlusion,
aortic/annulus injury, and valve dislodgment were
reported. In addition, we showed that BPD was not
associated with higher mortality, myocardial infarc-
tion, or bleeding rates, although there was a tendency
toward a higher rate of permanent pacemaker im-
plantation in patients who had BPD likely caused by
greater mechanical stress on the ventricular septum
and potential damage to the conduction branches and
the atrioventricular node. Interestingly, a statistically
higher rate of left bundle branch block (LBBB) was
reported in the no-BPD group. A possible explanation
for this ﬁnding might be the higher incidence of high-
degree atrioventricular block requiring permanentTABLE 5 Univariate and Multivariate Analysis for 1-Year All-Cause Mortality
Variables
Univariate Multivariate
Hazard Ratio 95% Conﬁdence Interval p Value Hazard Ratio 95% Conﬁdence Interval p Value
Balloon post-dilation 1.43 1.03–1.98 0.034 1.33 0.81–2.19 0.264
PVR moderate or severe 2.42 1.70–3.43 <0.001 2.36 1.56–3.56 <0.001
CRF* 2.18 1.59–2.99 <0.001 1.79 1.17–2.73 0.007
Chronic AF 1.46 1.07–1.99 0.016 1.62 1.04–2.52 0.034
NYHA functional class III–IV 1.84 1.27–2.67 0.001 1.41 0.84–2.38 0.196
Log-EuroSCORE 1.01 1.00–1.02 0.003 1.00 0.99–1.01 0.935
Baseline MR moderate or greater 1.45 1.09–1.94 0.011 1.25 0.83–1.89 0.284
Previous MI 1.28 0.91–1.79 0.148 1.31 0.81–2.12 0.268
Age 0.99 0.97–1.01 0.377
Female 0.86 0.65–1.13 0.270
Previous TIA/stroke 1.29 0.85–1.96 0.235
LVEF <35% 1.12 0.76–1.67 0.557
sPAP >60 mm Hg 1.33 0.86–2.06 0.194
Baseline AR moderate or greater 1.22 0.91–1.64 0.181
Previous PPM 1.02 0.68–1.55 0.905
Hypertension 0.82 0.59–1.15 0.250
Previous PCI 1.15 0.86–1.55 0.342
Previous CABG 0.91 0.61–1.35 0.638
Previous SAVR 0.44 0.11–1.77 0.249
COPD 1.08 0.78–1.48 0.642
PVD 1.15 0.85–1.54 0.364
Valve-in-valve 0.99 0.50–1.94 0.979
*Deﬁned as a glomerular ﬁltration rate <30 ml/h.
AF ¼ atrial ﬁbrillation; AR ¼ aortic regurgitation; MI ¼ myocardial infarction; sPAP ¼ systolic pulmonary artery pressure; PCI ¼ percutaneous coronary intervention; other
abbreviations as in Tables 1 and 4.
TABLE 6 Univariate and Multivariate Analyses for 1-Year Cardiovascular Mortality
Variables
Univariate Analysis Multivariate Analysis
Hazard Ratio 95% Conﬁdence Interval p Value Hazard Ratio 95% Conﬁdence Interval p Value
Balloon post-dilation 1.59 1.01–2.51 0.046 1.48 0.74–2.97 0.265
PVR moderate or severe 2.62 1.61–4.25 <0.001 2.60 1.45–4.67 0.001
CRF* 1.90 1.19–3.02 0.007 1.74 0.93–3.23 0.081
Previous MI 1.83 1.17–2.86 0.008 1.48 0.77–2.87 0.240
Log-EuroSCORE 1.01 1.00-1.03 0.019 1.00 0.98–1.02 0.823
Age 0.97 0.95–100 0.059 0.96 0.92–0.99 0.014
Baseline MR moderate or greater 1.48 0.98–2.34 0.062 1.13 0.63–2.02 0.689
Chronic AF 1.23 0.78–1.96 0.376
NYHA functional class III–IV 1.19 0.74–1.90 0469
Female 0.86 0.57–1.28 0.448
Previous TIA/stroke 0.97 0.46–1.80 0.779
LVEF <35% 1.32 0.77–2.26 0.309
sPAP >60 mm Hg 1.06 0.54–2.11 0.859
Baseline AR moderate or greater 1.10 0.71–1.70 0.668
Previous PPM 0.83 0.43–1.60 0.580
Hypertension 0.91 0.55–1.51 0.722
Previous PCI 1.00 0.65–1.55 0.993
Previous CABG 1.21 0.72–2.04 0.479
Previous SAVR 0.92 0.23–3.73 0.906
COPD 1.11 0.71–1.76 0.642
PVD 1.04 0.68–1.61 0.845
Valve-in-valve 1.67 0.76–3.64 0.197
*Deﬁned as a glomerular ﬁltration rate <30 ml/h.
Abbreviations as in Tables 1, 4, and 5.
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1020pacemaker implantation in the BPD group. Because
either the LBBB or the third-degree atrioventricular
block belongs to the spectrum of the same pathology,
it is possible that in patients who received BPD, a
higher degree of conduction disturbance developed,
thus determining lower frequency of an LBBB.
Recent data have suggested that post-dilation of a
transcatheter heart valve was associated with higher
rates of cerebrovascular events (5,6). These ﬁndings
were not conﬁrmed in this larger analysis, where
cerebral embolic events were similar between groups
both acutely and at mid-term follow-up. This differ-
ence might be explained by different techniques and
balloons used to accomplish BPD or by characteristics
of the self-expanding prosthesis itself. In fact,
we might speculate that the longer stent of the
CoreValve, as well as the fabric skirt that covers a
larger part of the frame compared with the balloon-
expandable SAPIEN valve (Edwards Lifesciences,
Irvine, California) allows fewer calciﬁc particle emb-
olisms from the aortic valve during post-dilation.
However, this explanation is hypothesis generating
only and needs to be demonstrated by dedicated
analyses. Another possible explanation for these dis-
crepancies in terms of neurological events between
previous studies and this analysis might be the lowerbaseline risk proﬁle of the patient population enrolled
in the present study.
STUDY LIMITATIONS. First, the transthoracic and
transesophageal echocardiograms were read locally
at the participating site. Grading of PVR may be het-
erogeneous across readers and sites. However, all
local site readings were performed by level 3 echo-
cardiographers with signiﬁcant experience in TAVR
and graded according to the standardized VARC
deﬁnitions (11). Second, the indications and tech-
nique of BPD, as well as balloon choices, were left to
the discretion of the physician of each site. Third, the
exact mechanism of PVR (underexpansion, low
implantation, high implantation) was not available.
Finally, the dataset of the ClinicalService did not
incorporate detailed computed tomography data,
which may have provided information regarding
aortic valve morphology, distribution of aortic valve
calciﬁcation, and cover index, features that have
demonstrated to signiﬁcantly predict the need for
BPD after TAVR (5). However, the main objective of
this paper was to shed more light on the clinical
impact of this bailout technique in a larger TAVR
population than that previously reported in earlier
studies.
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1021CONCLUSIONS
This large multicenter analysis showed that
BPD was ineffective at reducing PVR after TAVR
with the self-expanding CoreValve in 37% of
cases. This strategy was safe and was not asso-
ciated with increased cerebrovascular events,mortality, myocardial infarction, and aortic root
injury rates.
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